Carboplatin
OncoPharm
00:00
Development purpose and approval history
John outlines carboplatin's deliberate design to reduce nephrotoxicity and summarizes its FDA approval and early trial dosing.
Play episode from 02:14
Transcript
John outlines carboplatin's deliberate design to reduce nephrotoxicity and summarizes its FDA approval and early trial dosing.
